Influenza vaccine safety data – 50 years and older (adjuvanted or high-dose inactivated injectable vaccines)

Data on this page show the responses of individuals aged 50 years and older who received an adjuvanted or high-dose inactivated (injectable) influenza vaccine in 2026 and completed an AusVaxSafety survey sent in the days following vaccination.

Adjuvanted or high-dose inactivated (injectable) influenza vaccines currently in use in this age group include:

• Fluad (individuals aged 50 years and over)
• Fluzone High-Dose (individuals aged 60 years and over).

These data provide a profile of what to expect in the days following your influenza vaccination and can assist in planning for vaccination.

Data on this page will be updated weekly throughout the 2026 influenza season.
 

AusVaxSafety's active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration.

Further information and resources on the 2026 influenza vaccines are available on the NCIRS influenza immunisation webpage.